May 2025 in “The Journal of Rheumatology” Catatonia can be a rare sign of lupus, needing careful diagnosis and treatment.
May 2025 in “The Journal of Rheumatology” Purpura fulminans can signal underlying autoimmune disorders, not just infections.
May 2025 in “The Journal of Rheumatology” Lupus patients in Ghana face healthcare challenges, and the Oyemam Autoimmune Foundation is working to improve awareness and support.
May 2025 in “The Journal of Rheumatology” Bullous lupus can cause severe esophageal issues but responds well to corticosteroids and azathioprine.
May 2025 in “The Journal of Rheumatology” Atypical symptoms in lupus can indicate different kidney issues.
May 2025 in “The Journal of Rheumatology” Correct diagnosis is crucial for treating overlapping conditions like NMOSD and SLE effectively.
May 2025 in “The Journal of Rheumatology” Middle-aged women with dilated cardiomyopathy should be screened for antiphospholipid syndrome.
May 2025 in “The Journal of Rheumatology” Early recognition and a team approach are crucial for managing diffuse alveolar hemorrhage in antiphospholipid syndrome.
May 2025 in “The Journal of Rheumatology” Antiphospholipid syndrome can severely damage adrenal glands, requiring early diagnosis and treatment.
May 2025 in “The Journal of Rheumatology” SLE can cause unusual gastrointestinal symptoms, and immunosuppressive therapy can be effective.
October 2024 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in improving treatment outcomes and staying updated on various health conditions.
Removing SIX1 in fat cells reduces skin fibrosis.
September 2022 in “Institutional Repositories DataBase (IRDB)” Adipose-derived stem cells can be transformed into hair-forming cells using specific extracellular vesicles, offering potential for hair regeneration therapies.
April 2021 in “Journal of Law Public Policies and Human Sciences” The described COVID-19 treatments seemed effective in influencing the disease's course, duration, and severity.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
96 citations
,
December 2022 in “Pneumologie” The guideline offers current advice for diagnosing and treating Long- and Post-COVID symptoms.
June 2023 in “Fundamental & clinical pharmacology” JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
July 2024 in “Journal of Investigative Dermatology” A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.
June 2015 in “Reactions Weekly” A man developed alopecia areata after starting cancer treatment with vandetanib.
December 2022 in “International Journal of Molecular Sciences” Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
7 citations
,
January 2022 in “SAGE open medical case reports” Upadacitinib successfully treated a child's severe skin and hair loss issues.
9 citations
,
May 2021 in “Molecules” New indole-based compounds, particularly cemtirestat, show promise as dual-function drugs for diabetic complications.
12 citations
,
July 2023 in “Journal of the European Academy of Dermatology and Venereology” Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.
June 2026 in “Frontiers in Immunology” Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.